The treatment of multiple sclerosis has made enormous progress thanks to highly effective disease-modifying therapies, in particular anti-CD20 antibodies. For most newly diagnosed patients, a life without disability is realistic. However, the focus is now shifting from preventing acute relapses to combating the insidious progression of disability. New approaches target cellular mechanisms in the CNS and the promotion of remyelination.
Autoren
- Dr. Ulf Blanke
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
You May Also Like
- Psychooncology
Communication as the key to therapy adherence
- Cardiology
Minimally invasive – the quiet triumph of modern heart surgery
- Schizophrenia in the early-onset stage
Which antipsychotic should be used for treatment-naive patients?
- Diarrhea in children
The problem of parental expectations
- From symptom to diagnosis
Multilocular cystic renal cell carcinoma (MCRCC)
- Shaping the Future with LLM & Co.
AI in Everyday Clinical Practice: Friend or Foe?
- Ulcerative colitis: current evidence on anti-inflammatory therapies
Remission induction and maintenance with biologics and JAK-i
- Bronchiectasis